LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP5 | 1 | C20 | 72 | hr | 1476 | 1061 | 3694 | 0.2872 | -0.1875 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP5 | 2 | C20 | 72 | hr | 1476 | 1065 | 3694 | 0.2883 | -0.1857 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP5 | 3 | C20 | 72 | hr | 1476 | 870 | 3694 | 0.2355 | -0.2736 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP6 | 1 | C20 | 72 | hr | 1476 | 915 | 3694 | 0.2477 | -0.2533 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP6 | 2 | C20 | 72 | hr | 1476 | 1221 | 3694 | 0.3305 | -0.1153 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP6 | 3 | C20 | 72 | hr | 1476 | 1112 | 3694 | 0.3010 | -0.1645 |
| SK-BR-3 | MK2206 | 3.33 | uM | LJP6 | 1 | F02 | 72 | hr | 1476 | 2103 | 3694 | 0.5693 | 0.2825 |
| SK-BR-3 | MK2206 | 3.33 | uM | LJP6 | 2 | F02 | 72 | hr | 1476 | 1992 | 3694 | 0.5393 | 0.2324 |
| SK-BR-3 | MK2206 | 3.33 | uM | LJP6 | 3 | F02 | 72 | hr | 1476 | 2167 | 3694 | 0.5866 | 0.3113 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 1476 | 1208 | 3694 | 0.3270 | -0.1212 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 2 | A14 | 72 | hr | 1476 | 1427 | 3694 | 0.3863 | -0.0224 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 1476 | 1412 | 3694 | 0.3822 | -0.0292 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 1 | N14 | 72 | hr | 1476 | 3899 | 3694 | 1.0555 | 1.0924 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 2 | N14 | 72 | hr | 1476 | 3613 | 3694 | 0.9781 | 0.9635 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 3 | N14 | 72 | hr | 1476 | 3896 | 3694 | 1.0547 | 1.0911 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 1 | H02 | 72 | hr | 1476 | 2555 | 3694 | 0.6917 | 0.4863 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 2 | H02 | 72 | hr | 1476 | 2529 | 3694 | 0.6846 | 0.4746 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 3 | H02 | 72 | hr | 1476 | 2658 | 3694 | 0.7195 | 0.5328 |
| SK-BR-3 | NU7441 | 3.33 | uM | LJP5 | 1 | C08 | 72 | hr | 1476 | 2783 | 3694 | 0.7534 | 0.5891 |
| SK-BR-3 | NU7441 | 3.33 | uM | LJP5 | 2 | C08 | 72 | hr | 1476 | 2645 | 3694 | 0.7160 | 0.5269 |
| SK-BR-3 | NU7441 | 3.33 | uM | LJP5 | 3 | C08 | 72 | hr | 1476 | 2603 | 3694 | 0.7047 | 0.5079 |
| SK-BR-3 | Dactolisib | 3.33 | uM | LJP5 | 1 | M14 | 72 | hr | 1476 | 1340 | 3694 | 0.3628 | -0.0617 |
| SK-BR-3 | Dactolisib | 3.33 | uM | LJP5 | 2 | M14 | 72 | hr | 1476 | 1415 | 3694 | 0.3831 | -0.0278 |
| SK-BR-3 | Dactolisib | 3.33 | uM | LJP5 | 3 | M14 | 72 | hr | 1476 | 1577 | 3694 | 0.4269 | 0.0452 |
| SK-BR-3 | NVP-TAE684 | 3.33 | uM | LJP6 | 1 | K14 | 72 | hr | 1476 | 1527 | 3694 | 0.4134 | 0.0227 |